Low p27Kip1 expression is an independent adverse prognostic factor in patients with multiple myeloma

Clinical Cancer Research

Volumn 9, Issue 2, 2003, Pages 820-826

  Filipits, Martin ^a,b   Pohl, Gudrun ^a   Stranzl, Thomas ^a   Kaufmann, Hannes ^a   Ackermann, Jutta ^a   Gisslinger, Heinz ^a   Greinix, Hildegard ^a   Chott, Andreas ^a   Drach, Johannes ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; DEXAMETHASONE; DOXORUBICIN; PROTEIN P27; VINCRISTINE; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME 13Q; CHROMOSOME DELETION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; BIOPSY; CHROMOSOME 13; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; MIDDLE AGED; MORTALITY; NOTE; PATHOLOGY; SURVIVAL; TIME; TUMOR SUPPRESSOR GENE;

ADULT; BIOPSY; CELL CYCLE PROTEINS; CHROMOSOMES, HUMAN, PAIR 13; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 0037312547     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Sherr, C. J. Cancer cell cycles. Science (Wash. DC), 274: 1672-1677, 1996.
2. Sherr, C. J., and Roberts, J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.
3. Morgan, D. O. Principles of CDK regulation. Nature (Lond.), 374: 131-134, 1995.
4. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
5. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals: Cell, 78: 59-66, 1994.
6. CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev., 9: 650-662, 1995.
7. LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sanduh, C., Chou, H. S., Fattaey, A., and Harlow, E. New functional activities for the p21 family of CDK inhibitors. Genes Dev., 11: 847-862, 1997.
8. Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblast. EMBO J., 18: 1571-1583, 1999.
9. 1-phase progression. Genes Dev., 13: 1501-1512, 1999.
10. Kip1 is haplo-insufficient for tumor suppression. Nature (Lond.), 396: 177-180, 1998.
11. Katayose, Y., Kim, M., Rakkar, A. N. S., Li, Z., Cowan, K. H., and Seth. P. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res., 57: 5441-5445, 1997.
12. kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol. Cell, 1: 553-563, 1998.
13. Durand, B., Gao, F. B., and Raff, M. Accumulation of the cyclin-dependent kinase inhibitor p27/Kip1 and the timing of oligodendrocyte differentiation. EMBO J., 16: 306-317, 1997.
14. Kip1 in osteoblast-like cells during differentiation with parathyroid hormone. Endocrinology, 138: 1995-2004, 1997.
15. Kip1 safeguards against inflammatory injury. Nat. Med., 4: 575-580, 1998.
16. Kip1 on resistance of tumor cells to anticancer agents. Nat. Med., 2: 1204-1210, 1996.
17. Erlanson, M., Portin, C., Linderholm, B., Lindh, J., Roos, G., and Landberg, G. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. Blood, 92: 770-777, 1998.
18. Kip1. Br. J. Haematol., 105: 730-736, 1999.
19. Kip1 is abnormally expressed in diffuse large B-cell lymphomas and is associated with an adverse clinical outcome. Br. J. Cancer, 80: 1427-1434, 1999.
20. Chiarle, R., Budel, L. M., Skolnik, J., Frizzera, G., Chilosi, M., Corato, A., Pizzolo, G., Magidson, J., Montagnoli, A., Pagano, M., Maes, B., De Wolf-Peeters, C., and Inghirami, G. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood, 95: 619-626, 2000.
21. Chronic Leukemia-Myeloma Task Force. Proposed guidelines for protocol studies: II. Plasma cell myeloma. Cancer Chemother. Rep., 4: 145-158, 1973.
22. Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., and Vesole, D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br. J. Haematol., 102: 1115-1123, 1998.
23. Wijdenes, J., Vooijs, W. C., Clément, C., Post, J., Morard, F., Vita, N., Laurent, P., Sun, R-X., Klein, B., and Dore, J-M. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br. J. Haematol., 94: 318-323, 1996.
24. Filipits, M., Jaeger, U., Pohl, G., Stranzl, T., Simonitsch, I., Kaider, A., Skrabs, C., and Pirker, R. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin. Cancer Res., 8: 729-733, 2002.
25. Kip1 protein: prognostic implications in primary breast cancer. Nat. Med., 3: 227-230, 1997.
26. Zojer, N., Königsberg, R., Ackermann, J., Fritz, E., Dallinger, S., Krömer, E., Kaufmann, H., Riedl, L., Gisslinger, H., Schreiber, S., Heinz, R., Ludwig, H., Huber, H., and Drach, J. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood, 95: 1925-1930, 2000.
27. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
28. Cox, D. R. Regression models and life tables. J. R. Stat. Soc., 34: 187-220, 1972.
29. Königsberg, R., Zojer, N., Ackermann, J., Krömer, E., Kittler, H., Fritz, E., Kaufmann, H., Nösslinger, T., Riedl, L., Gisslinger, H., Jäger, U., Simonitsch, I., Heinz, R., Ludwig, H., Huber, H., and Drach, J. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J. Clin. Oncol., 18: 804-812, 2000.
30. Sonneveld, P. Multidrug resistance in haematological malignancies. J. Intern. Med., 247: 521-534, 2000.
31. Filipits, M., Drach, J., Pohl, G., Schuster, J., Stranzl, T., Ackermann, J., Königsberg, R., Kaufmann, H., Gisslinger, H., Huber, H., Ludwig, H., and Pirker, R. Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. Clin. Cancer Res., 5: 2426-2430, 1999.
32. Chauhan, D., and Anderson, K. C. Apoptosis in multiple myeloma: therapeutic implications. Apoptosis, 6: 47-55, 2001.
33. Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A., and Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood, 93: 1658-1667, 1999.
34. kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene, 19: 4319-4327, 2000.
35. Desikan, R., Barlogie, B., Sawyer, J., Ayers, D., Tricot, G., Badros, A., Zangari, M., Munshi, N. C., Anaissie, E., Spoon, D., Siegel, D., Jagannath, S., Vesole, D., Epstein, J., Shaughnessy, J., Fassas, A., Lim, S., Roberson, P., and Crowley, J. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood, 95: 4008-4010, 2000.
36. Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Geneviève, F., Zandecki, M., Laï, J-L., Leleu, X., Jouet, J-P., Bauters, F., Harousseau, J-L., Bataille, R., and Mary, J-Y. on behalf of the Intergroupe Francophone du Myélome (IFM). Chromosome 13 abnormalities identified by FISH analysis and serum 2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood, 15: 1566-1571, 2001.
37. An, B., Goldfarb, R. H., Siman, R., and Dou, Q. P. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ., 5: 1062-1075, 1998.
38. Hideshima, T., Richardson, P., Chauhan, D., Palombella. V. J., Elliott, P. J., Adams, J., and Anderson, K. C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res., 61: 3071-3076, 2001.
39. Richardson, P. G., Berenson, J., Irwin, D., Jagannath, S., Traynor, A., Rajkumar, V., Alsina, M., Kuter, D., Srkalovic, G., Siegel, D., Barlogie, B., Alexanian, R., Orlowski, R., Esseltine, D., Kauffman, M., Adams, J., Schenkein, D. P., and Anderson, K. C. Phase Il study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy. Blood, 98: 774a, 2001.